Kadmon Holdings Inc (NASDAQ:KDMN) has been assigned an average recommendation of “Hold” from the eight analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.85.

Several equities analysts have recently issued reports on KDMN shares. Zacks Investment Research raised Kadmon Holdings from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Tuesday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kadmon Holdings in a research report on Monday, June 26th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $7.00 price target on shares of Kadmon Holdings in a research report on Friday, July 14th. Finally, ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Shares of Kadmon Holdings (NASDAQ:KDMN) traded down 0.30% during mid-day trading on Friday, hitting $3.35. 375,902 shares of the stock traded hands. The company’s market capitalization is $173.68 million. Kadmon Holdings has a 1-year low of $2.86 and a 1-year high of $8.02. The company’s 50-day moving average price is $3.12 and its 200 day moving average price is $3.12.

Kadmon Holdings (NASDAQ:KDMN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.05. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.46 million. Kadmon Holdings’s revenue for the quarter was down 53.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.40) EPS. Equities research analysts forecast that Kadmon Holdings will post ($1.58) EPS for the current fiscal year.

In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 349,661 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $2.60, for a total value of $909,118.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders acquired 14,707 shares of company stock valued at $34,294 and sold 687,073 shares valued at $1,863,337.

A number of large investors have recently modified their holdings of the business. Wells Fargo & Company MN raised its position in Kadmon Holdings by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after buying an additional 8,742 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in Kadmon Holdings in the 2nd quarter worth about $114,000. KCG Holdings Inc. purchased a new position in Kadmon Holdings in the 1st quarter worth about $124,000. Bank of New York Mellon Corp raised its position in Kadmon Holdings by 302.3% in the 1st quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock worth $167,000 after buying an additional 34,794 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Kadmon Holdings in the 1st quarter worth about $158,000.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/kadmon-holdings-inc-kdmn-given-average-recommendation-of-hold-by-analysts/1599631.html.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Analyst Recommendations for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.